STOK at a glance
Stoke Therapeutics, Inc. (STOK, SEC CIK 1623526) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on September 25, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Stoke Therapeutics, Inc. (STOK) reported revenue of $184.4 million (up 404.5% from FY2024) and a net loss of $6.9 million. Diluted EPS was -$0.12.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Stoke Therapeutics, Inc. (STOK) shares worth $897.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Allan Jonathan on October 2, 2026 of 627 shares at $26.33 per share.
- In the last 90 days, STOK insiders reported 0 open-market purchases ($0) and 12 open-market sales ($1.1M) on Form 4, a net sale of $1.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $184.4M
- +404.5% vs prior year
- Insiders · 90 days
- 0 buys · 12 sells
- Net −$1.1M
- 13F holders
- 27 funds
- $897.0M · +0 vs prior quarter
- Latest 8-K
- Sep 25, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: RNA-based medicines using proprietary TANGO platform to upregulate protein expression for treating severe genetic diseases
- New focus: Phase 3 study of zorevunersen for Dravet syndrome initiated May 2025, plus Phase 1 study of STK-002 for autosomal dominant optic atrophy
- Strategic shift: Emphasis on rapid commercial preparation in US, Canada, Mexico for zorevunersen; global commercial partner Biogen for other territories
- Notable metric: EMPEROR Phase 3 enrollment target ~150 patients; OLE studies sustained seizure reduction through 3 years in 74 patients enrolled
- Unique fact: Zorevunersen granted FDA Breakthrough Therapy Designation Dec 2024; Phase 1/2a and OLE data published in New England Journal of Medicine March 2026
Risk Factors
- Regulatory risk from FDA clinical holds: partial hold on zorevunersen doses removed, future holds possible delaying development
- Macroeconomic exposure: potential impacts from inflation, fluctuating interest rates, tariffs, recessions, and government shutdowns on operations
- Supply chain risk: dependency on third-party CMOs for clinical and commercial manufacturing supply and backup sources
- Competitive risk: uncertainty if regulatory labeling excludes secondary endpoints potentially weakening competitive positioning
- Financial risk: history of losses with anticipated continued deficits and need for additional funding before profitability achievable
Management Discussion & Analysis
- Revenue $184.4M in 2025 vs $36.6M in 2024, up $147.8M mainly from Biogen collaboration ($168.3M in 2025) offset by Acadia decline
- Net loss $6.9M in 2025 vs $89.0M in 2024; operating loss improved to $20.6M from $101.4M; operating margin approx. -11.2% vs -277.1%
- Best segment: Biogen collaboration revenue $168.3M in 2025, no revenue in 2024; worst: ADOA R&D costs mostly flat ($5.1M vs $5.8M) with limited impact on revenue
- Cash $390.9M at end 2025 vs $246.7M end 2024; capital raised via equity offerings netting $168.8M in 2025; no dividends or buybacks disclosed; expected to fund operations into 2028
- Forward outlook: expect increased R&D and SG&A costs to support clinical development and commercialization; risks from clinical, regulatory, and financing uncertainties remain
AI summary of the STOK 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly emphasized clinical risk: STK-002 entered Phase 1 OSPREY dosing in February 2026, increasing exposure to early-stage trial failure
- Regulatory risk: Supreme Court’s June 2024 Chevron reversal may increase challenges to FDA regulations and approval requirements
- Near-term operational risk: Hospital staffing shortages may delay trial enrollment, site visits, evaluations, or patient dosing
- Market risk: Dravet syndrome incidence approximately one in 15,600 births, limiting enrollment and commercial-market size
- Financial risk: Continued operating losses require additional funding before potential product sales support profitability
AI summary of the STOK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Edward M. Kaye resigning as Class III director and R&D Committee member effective September 23, 2026
- Board appointed Alexander (Bo) Cumbo as independent Class III director through the 2028 Annual Meeting
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investors should review the accompanying press release for reported figures and management commentary
Item EX-99.1: Item EX-99.1
- Phase 3 EMPEROR enrollment complete at 162 patients, with primary data readout expected Q3 2027 and rolling U.S. NDA completion targeted H2 2027
- FDA pre-NDA meeting planned H2 2026, with rolling U.S. NDA submission targeted Q1 2027
Item 8.01: Other Events
- Stoke authorized up to $200 million in at-the-market common-stock sales through Cantor Fitzgerald
- Potential equity issuance creates shareholder dilution and provides additional financing flexibility
AI summaries of STOK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for STOK
Don't miss the next STOK filing
- Alerts as it files. A push when STOK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut STOK, by share count.
- Ask anything. An AI agent that reads every STOK filing and answers with sources.
STOK alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Allan Jonathan | Sell | Oct 2, 2026 | 627 | $26.33 |
| Ticho Barry | Sell | Oct 1, 2026 | 1,051 | $26.16 |
| Cumbo Alexander | A | Sep 23, 2026 | 39,674 | - |
| Ticho Barry | Sell | Sep 1, 2026 | 1,600 | $31.06 |
| Ticho Barry | Sell | Sep 1, 2026 | 3,945 | $30.51 |
| Allan Jonathan | Sell | Aug 18, 2026 | 145 | $32.47 |
| Kaye Edward M. MD | Sell | Aug 18, 2026 | 11,930 | $32.01 |
| Ticho Barry | Sell | Aug 18, 2026 | 242 | $32.47 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $8.8M | $36.6M | $184.4M |
| Operating Income | - | -$101.4M | -$20.6M |
| Net Income | -$104.7M | -$89.0M | -$6.9M |
| Op. Margin | - | -277.3% | -11.2% |
| Net Margin | -1192.5% | -243.4% | -3.7% |
| Balance Sheet | |||
| Total Assets | - | $271.6M | $418.4M |
| Equity | $159.6M | $229.0M | $352.5M |
| ROE | -65.6% | -38.9% | -2.0% |
| Per Share | |||
| EPS | - | $-1.65 | $-0.12 |
| Cash Flow | |||
| Operating CF | -$81.1M | -$86.9M | $45.6M |
| CapEx | - | $203K | $670K |
Source: XBRL data in Stoke Therapeutics, Inc. (STOK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate STOK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $897.0M |
| Q1 2026 | 27 | $832.1M |
| Q4 2025 | 22 | $759.6M |
| Q3 2025 | 24 | $572.3M |
| Q2 2025 | 23 | $282.0M |
| Q1 2025 | 19 | $94.7M |
| Q4 2024 | 18 | $65.6M |
| Q3 2024 | 14 | $35.3M |
- T. Rowe Price Group+727.6K (+38%)
- State Street Corp+575.7K (+25%)
- BlackRock+491.6K (+9%)
- Citadel Advisors LLC+366.3K (+298%)
- Vanguard Capital Management LLC+231.3K (+10%)
- Bank of America Corp−283.4K (-52%)
- Goldman Sachs Group−255.4K (-31%)
- Millennium Management−211.1K (-45%)
- Invesco Ltd−82.4K (-55%)
- FMR LLC (Fidelity)−70.6K (-1%)
- Two Sigma Investments+62.4K
- Blackstone Group−30.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
STOK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
STOK SEC filings: frequently asked questions
Are STOK insiders buying or selling?
In the last 90 days, Stoke Therapeutics, Inc. (STOK) officers, directors and 10% owners reported no open-market purchases and 12 open-market sales worth $1.1 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold STOK stock?
As of June 30, 2026, the largest Stoke Therapeutics, Inc. (STOK) holders among the 13F filers tracked by SignalX were BlackRock ($192.3 million), FMR LLC (Fidelity) ($173.8 million), Morgan Stanley ($113.0 million), State Street Corp ($93.3 million), T. Rowe Price Group ($87.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was STOK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Stoke Therapeutics, Inc. (STOK) reported revenue of $184.4 million (up 404.5% from FY2024) and a net loss of $6.9 million. Diluted EPS was -$0.12. The figures come from the XBRL data in the 10-K.
What are the main risks in STOK's latest 10-K?
In the 10-K filed March 16, 2026, Stoke Therapeutics, Inc. (STOK) flagged: Regulatory risk from FDA clinical holds: partial hold on zorevunersen doses removed, future holds possible delaying development. Macroeconomic exposure: potential impacts from inflation, fluctuating interest rates, tariffs, recessions, and government shutdowns on operations. (AI summary of the Risk Factors section.)
What did STOK report in its latest 8-K?
Stoke Therapeutics, Inc. (STOK) filed an 8-K on September 25, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Edward M. Kaye resigning as Class III director and R&D Committee member effective September 23, 2026.
What are the latest STOK SEC filings?
Stoke Therapeutics, Inc. (STOK) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on September 25, 2026 and a Form 4 insider filing on October 2, 2026.
What is STOK's SEC CIK number?
Stoke Therapeutics, Inc. (STOK)'s SEC Central Index Key (CIK) is 1623526. EDGAR lists every STOK filing under that number.
Ask anything about STOK
The research agent reads STOK's filings, financials, insider trades and 13F holders, then answers with sources.